MDMA,politics and medical research: Have we thrown the baby out with the bathwater?

Bell C.J. , Hood S.D. , Nutt D.J. (2005) Acute tryptophan depletion. Part II: clinical effects and implications. ANZ J Psychiatry 39(7): 565—574

Bonnie, Whitebread C H (1999) The Marijuana Conviction: A History of Marijuana Prohibition in the United States. New York: Drug Policy Alliance. July 1999, 368—370

Cami J. , Farre M. , Mas M. , Roset P.N. , Poudevida S. , Mas A. , San L. , de la Torre R. (2000) Human pharmacology of 3,4-methylenedioxymethamphetamine (`ecstasy'): psychomotor performance and subjective effects. J Clin Psychopharmacol 20: 455—466

Greer G.R. , Tolbert R. (1986) Subjective reports of the effects of MDMA in a clinical setting. J Psychoactive Drugs 18(4): 319—327

Grinspoon L. , Bakalar J.B. (1995) Marihuana as medicine: a plea for reconsideration . JAMA 273(23): 1875—1876

Grob C. ( 2002) Appendix B., Deconstructing Ecstasy: The Politics of MDMA research. From `Hallucinogens — A Reader'. Published by Tarcher/Putnam.

Halpern J.H. , Pope H.G. , Sherwood A.R. , Barry S. , Hudson J.I. , Yurgelun-Todd D. (2004) Residual neuropsychological effects of illicit MDMA in individuals with minimal exposure to other drugs. Drug Alcohol Depend 75: 135—147

Hood S.D. , Bell C.J. , Nutt D.J. (2005) Acute tryptophan depletion. Part I: rationale and methodology. ANZ J Psychiatry 39(7): 558—564

Huizink A.C. , Ferdinand R.F. , van der Ende J. , Verhulst F.C. (2006) Symptoms of anxiety and depression in childhood and use of MDMA: prospective, population based study. BMJ 332: 825—828

Iverson L. (2006) Speed, ecstasy, ritalin: the science of amphetamines. Chapter 8, Ecstasy. Pages 151—152. Oxford University Press, Oxford

Johnson M.P. , Hoffma A.J. , Nichols D.E. (1986) Effects of the enantiomers of MDA, MDMA and related analogues on [3H]serotonin and [3H]dopamine release from superfused rat brain slices. Eur J Pharmacol 132: 269—296

Lee M.A. , Shalin B. (1992) Acid dreams. The complete social history of LSD: the CIA, the sixties and beyond. Chapter 3, Pages 87—95. Grove Press, New York

Lieb R. , Schuetz C. , Pfister H. , von Sydow K. , Wittchen H. (2002) Mental disorders in ecstasy users: a prospective-longitudinal investigation. Drug Alcohol Depend 68(2): 195

Liechti M.E. (2001) Gender differences in the subjective effects of MDMA. Psychopharmacology 154:161—168

Liester M.B. , Grob C.S. , Bravo G.L. , Walsh R.N. (1992) Phenomenology and sequelae of 3,4-methylenedioxymethamphetamine use. J Nervous Mental Dis 180: 345—352

Ludewig S. , Ludewig K. , Hasler F. , Vollenweides F.X. (2003) No lasting effects of moderate doses of MDMA on memory performance and mood states in healthy humans. Biol Psychiatry 53 (Suppl): 2055

Molliver M.E. , Berger U.V. , Mamounas L.A. , Molliver D.C. , O'Hearn E. , Wislon M.A. (1990) Neurotoxicity of MDMA and related compounds: anatomic studies. Ann NY Acad Sci 600: 640—664

National Criminal Intelligence Service (2001 ) UK Threat Assessment 2001, produced by the National Criminal Intelligence Service

Nutt D.J. , King L.A. , Saulsbury W. , Blakemore C. (2007) The development of a rational scale to assess the harm of drugs of potential misuse. The Lancet 369: 1047—1053

Office of National Statistics (2002) — Deaths related to drug poisoning in England and Wales 1993—2000 and 1998—2002. Health Statistic Quarterly, Spring 2003 and Spring 2004

Office of National Statistics (2002 and 2003) Mortality Statistics — Review of the Register General on Death in England and Wales, 2002 and 2003

Parrott A.C. (2007) The psychotherapeutic potential of MDMA (3,4-methylenedioxymethamphetamine): an evidence-based review. Psychopharmacology 191: 181—193

Reneman L. , Endert E. , de Bruin K. , Lavalaye J. , Feenstra M.G. , de Wolff F.A. , Booij J.L. (2002) The acute and chronic effects of MDMA (`Ecstasy') on cortical 5-HT2A receptors in rat and human brain Neuropsychopharmacology 26: 387396.10.1038/S0893-133X(01)00366-9

Ricaurte G. , Bryan G. , Strauss L. , Seiden L. , Schuster C. (1985) Hallucinogenic amphetamine selectively destroys brain serotonin nerve terminals. Science 229: 986—988

Riedlinger J. , Montagne M. (2001) Potential clinical uses for MDMA. In Holland J (Ed.). Ecstasy: the complete guide: a comprehensive review of the risks and benefits of MDMA. Inner Traditions 261—272

Sessa B. (2007) Is there a case for MDMA-assisted psychotherapy in the UK? J Psychopharmacol 21: 220—221

Shulgin A.T. (1986) The background and chemistry of MDMA. J Psychoactive Drugs 18: 291—304

Steele D.M. , Nichols D.E. , Yim G K W (1987) Sterochemical effects of 3,4-methylenedioxymethlyamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) and related amphetamine derivatives on inhibition of uptake of [3H]-monoamines into synaptosomes for different regions of rat brain. Biochem Pharmacol 36: 2297—2303

Sumnall H.R. , Cole J.C. , Jerome L. (2006) The varieties of ecstatic experience: an exploration of the subjective experiences of ecstasy. J Psychopharmacol 2006, Published: On-line

UK Home Office (1971) Misuse of drugs act. www.drugs.gov.uk

Vollenweider F.X. , Gamma A. , Liechti M. , Huber T. (1998a) Psychological and cardiovascular effects and short-term sequlae of MDMA (`ecstasy') in MDMA-naïve healthy volunteers. Neuropsychopharmacology 19: 241—251